Author

M. Ohh

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:metabolomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Ronchi· 1 shared C. Greenwood· 1 shared C. Ierano· 1 shared D. Avizonis· 1 shared D. Sorriento· 1 shared E. Puxeddu· 1 shared F. Liotti· 1 shared F. Zito Marino· 1 shared

Activity by Year

2017-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Ronchi

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A cell-autonomous PD-1/PD-L1 circuit promotes tumorigenicity of thyroid cancer cells by activating a SHP2/Ras/MAPK signalling cascade

F. Liotti, N. Kumar, N. Prevete, M. Marotta, D. Sorriento, C. Ierano, A. Ronchi, F. Zito Marino, S. Moretti, R. Colella, E. Puxeddu, S. Paladino, Y. Kano, M. Ohh, S. Scala, R. M. Melillo

This study shows PD-1 in thyroid cancer cells promotes tumorigenicity via SHP2/Ras/MAPK signaling, and blocking this circuit inhibits tumor growth.

bioRxiv · Sep 22, 2020 · PreprintCancer Biology

Translational and HIF1α-dependent metabolic reprograming underpin oncometabolomeplasticity and synergy between oncogenic kinase inhibitors and biguanides.

L. Hulea, S.-P. Gravel, M. Morita, M. Cargnello, O. Uchenunu, Y. K. Im, S. McLaughlan, O. Larsson, M. Ohh, T. Ferreira, C. Greenwood, G. Bridon, D. Avizonis, J. Ursini-Siegel, J. St-Pierre, , I. Topisirovic

This study identifies translational reprogramming of non-essential amino acid synthesis and HIF1-dependent reductive glutamine metabolism as key factors enabling synergy between kinase inhibitors and biguanides in cancer cells.

bioRxiv · Jul 8, 2017Cancer Biology